Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX)‘s stock had its “buy” rating reissued by research analysts at Cantor Fitzgerald in a note issued to investors on Wednesday. They currently have a $23.00 price target on the specialty pharmaceutical company’s stock. Cantor Fitzgerald’s price objective would suggest a potential upside of 62.54% from the company’s previous close.

The analysts wrote, “Valeant announced that the FDA confirmed it intends to issue a Voluntary Action Indicated (VAI) inspection classification for its Bausch + Lomb manufacturing facility in Tampa, Florida.””

VRX has been the subject of several other reports. J P Morgan Chase & Co set a $10.00 price objective on Valeant Pharmaceuticals International and gave the company a “hold” rating in a report on Monday, July 17th. BTIG Research reaffirmed a “neutral” rating on shares of Valeant Pharmaceuticals International in a report on Wednesday, May 10th. BMO Capital Markets reaffirmed a “market perform” rating on shares of Valeant Pharmaceuticals International in a report on Wednesday, May 10th. Guggenheim began coverage on Valeant Pharmaceuticals International in a report on Saturday, June 17th. They issued a “buy” rating and a $18.00 price objective for the company. Finally, Wells Fargo & Company reaffirmed an “underperform” rating and issued a $9.00 price objective on shares of Valeant Pharmaceuticals International in a report on Thursday, August 10th. Four investment analysts have rated the stock with a sell rating, fourteen have issued a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $17.31.

Shares of Valeant Pharmaceuticals International (NYSE VRX) traded up 1.80% during midday trading on Wednesday, reaching $14.15. The company’s stock had a trading volume of 13,556,665 shares. Valeant Pharmaceuticals International has a 12 month low of $8.31 and a 12 month high of $32.74. The firm’s market cap is $4.93 billion. The company has a 50-day moving average price of $16.35 and a 200-day moving average price of $13.38.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last announced its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.97 by $0.08. The firm had revenue of $2.23 billion during the quarter, compared to analysts’ expectations of $2.23 billion. Valeant Pharmaceuticals International had a positive return on equity of 59.89% and a negative net margin of 12.40%. The company’s quarterly revenue was down 7.7% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.88) EPS. Equities analysts expect that Valeant Pharmaceuticals International will post $3.89 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Valeant Pharmaceuticals International’s (VRX) Buy Rating Reiterated at Cantor Fitzgerald” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another website, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/08/16/valeant-pharmaceuticals-internationals-vrx-buy-rating-reiterated-at-cantor-fitzgerald.html.

Several large investors have recently added to or reduced their stakes in VRX. Gruss & Co. Inc. bought a new stake in Valeant Pharmaceuticals International during the first quarter worth approximately $104,000. Financial Architects Inc raised its stake in Valeant Pharmaceuticals International by 18.6% in the first quarter. Financial Architects Inc now owns 9,550 shares of the specialty pharmaceutical company’s stock worth $105,000 after buying an additional 1,500 shares during the period. Harbor Advisors LLC bought a new stake in Valeant Pharmaceuticals International during the first quarter worth approximately $110,000. WMS Partners LLC bought a new stake in Valeant Pharmaceuticals International during the first quarter worth approximately $116,000. Finally, Brave Asset Management Inc. bought a new stake in Valeant Pharmaceuticals International during the first quarter worth approximately $119,000. Hedge funds and other institutional investors own 50.96% of the company’s stock.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Stock Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related stocks with our FREE daily email newsletter.